This clinical trial aims to evaluate the safety and effectiveness of the Transvenous Artificial Tricuspid Valve System, LuX-Valve Plus System, Jenscare Scientific Co., Ltd. The study population consists of high-risk patients with severe or greater tricuspid regurgitation (TR) who are ineligible for surgical intervention and have demonstrated inadequate response to optimized medical therapy (OMT). This is a prospective, multicenter, randomized controlled trial. A total of 111 subjects who meet all inclusion criteria and none of the exclusion criteria will be enrolled. Participants will be randomized in a 2:1 ratio to one of the following groups: Treatment Group: Transvenous Artificial Tricuspid Valve System implantation + OMT Control Group: OMT alone All subjects will undergo serial follow-up assessments pre-treatment, during the treatment period, and post-procedure at 30 days, 3 months, 6 months, 1 year, and annually through 2-5 years. A summary report will be submitted to the regulatory authority at the 6-month time point. Subjects in the treatment group will have one extra follow-up visit at 7 days ± 3 days post-procedure or prior to discharge (whichever occurs first).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
126
Transvenous tricuspid valve replacement with Lux-Valve Plus System in patients with severe or greater Tricuspid Regurgitation despite optimal medical therapy (OMT)
Optimal medical therapy (OMT) as the control group for patients with severe or greater tricuspid regurgitation
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Incidence rate of composite endpoint events
Percentage (%) of participants achieving composite clinical success at 6 months. Composite clinical success is defined as meeting all of the following criteria: 1. Alive; 2. No heart failure rehospitalization; 3. Reduction in tricuspid regurgitation severity by ≥1 grade from baseline; 4. Improvement in New York Heart Association (NYHA) functional class by ≥1 class from baseline.
Time frame: 6 months post-treatment
Rate of Major Adverse Events (MAE)
The major adverse event (MAE) rate is defined as the occurrence of any of the following: Cardiac death Myocardial infarction Stroke New-onset renal failure requiring renal replacement therapy after the procedure Major bleeding (Grade ≥3b according to TVARC) Tricuspid valve re-intervention Device puncture site and vascular access complications Major cardiac structural complications Device-related pulmonary embolism Arrhythmia or conduction block requiring permanent pacemaker implantation
Time frame: 30 Day Post-treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.